ICAAC 45th

In Vitro Activity of the New Azole BAL4815 against Clinical Candida Isolates Comprising Resistant C. albicans and Less Susceptible Candida spp (click for details)
Efficacy, Safety, and Tolerability of three Different Dosing Regimens of BAL8557 Vs. Fluconazole in a Double-Blind, Randomized, Multicenter Trial for the Treatment of Esophageal Candidiasis in Immunocompromised Adults (click for details)
In vivo Efficacy of the triazole BAL8557 (BAL) Compared to Voriconazole (VOR), Itraconazole (ITC) and Caspofungin (CAS) By a New qPCR and Quantitative Culture in a Neutropenic Murine Model of Aspergillus flavus (click for details)
Dose Response Curves and Dose Fractionation Studies with BAL8557 in a Murine Model of Disseminated Candidiasis (click for details)
Antifungal Activity of BAL4815, a Novel Azole Against Dermatophytes and Emerging Non-Dermatophyte Fungi Including Zygomycetes (click for details)
In vitro activity of the new azole BAL4815 against clinical dermatophyte isolates (click for details)
Comparison of the MICs of Micafungin (MFGN) against Candida Bloodstream Isolates (BSI) Using the NCCLS M27-A2 (M27-A2), Antibiotic Medium 3 (AM3) and Sensititre Yeast0ne (SYO) Methods (click for details)
946;-1,3-D-Glucan (BGL) Antigenemia in Neutropenic Cancer Patients (Pts) with Invasive Aspergillosis (IA) and Candidiasis (IC) (click for details)
Antagonistic Interaction between Amphotericin B (AB) and Ravuconazole (RAV) Using the Bliss Independence Drug Interaction (BIDI) Model: In Vitro and In Vivo Correlations (click for details)
Posaconazole is Highly Effective as a Second-Line Agent in Zygomycosis: Summary of 91 Cases (click for details)


Subscribe to ICAAC 45th